title: Taurine chloramine differentially inhibits matrix metalloproteinase 1 and 13 synthesis in interleukin-1beta stimulated fibroblast-like synoviocytes.
abstract: It has been suggested that taurine chloramine (TauCl) plays an important role in the downregulation of proinflammatory mediators. However, little is known about its effect on the expression of matrix metalloproteinases (MMPs). In this study, we investigated the effects of TauCl on synovial expression of MMPs. The effects of TauCl on MMP expression in IL-1beta stimulated fibroblast-like synoviocytes (FLSs) were studied using the following techniques. Real-time PCR and semi-quantitative PCR were employed to analyze the mRNA expression of MMPs. ELISA was used to determine protein levels of MMPs. Western blot analyses were performed to analyze the mitogen-activated protein kinase and inhibitor of nuclear factor-kappaB (IkappaB) kinase signalling pathways. Finally, electrophoretic mobility shift assay and immunohistochemistry were used to assess localization of transcription factors. IL-1beta increased the transcriptional and translational levels of MMP-1 and MMP-13 in rheumatoid arthritis FLSs, whereas the levels of MMP-2 and MMP-9 were unaffected. TauCl at a concentration of 400 to 600 micromol/l greatly inhibited the transcriptional and translational expression of MMP-13, but the expression of MMP-1 was significantly inhibited at 800 micromol/l. At a concentration of 600 micromol/l, TauCl did not significantly inhibit phosphorylation of mitogen-activated protein kinase or IkappaB degradation in IL-1beta stimulated rheumatoid arthritis FLSs. The degradation of IkappaB was significantly inhibited at a TauCl concentration of 800 micromol/l. The inhibitory effect of TauCl on IkappaB degradation was confirmed by electrophoretic mobility shift assay and immunochemical staining for localization of nuclear factor-kappaB. TauCl differentially inhibits the expression of MMP-1 and MMP-13, and inhibits expression of MMP-1 primarily through the inhibition of IkappaB degradation, whereas it inhibits expression of MMP-13 through signalling pathways other than the IkappaB pathway.
authors: East-West Bone & Joint Research Center, East-West Neo Medical Center, Kyung Hee University, Sangil-dong, Gangdong-gu, Seoul, Republic of Korea. labrea46@yahoo.co.kr
authors: Kyoung Soo
authors: KS
authors: Kim
authors: Eun Kyung
authors: EK
authors: Park
authors: Seung Min
authors: SM
authors: Ju
authors: Hye-Sook
authors: HS
authors: Jung
authors: Jun Soo
authors: JS
authors: Bang
authors: Chaekyun
authors: C
authors: Kim
authors: Yeon-Ah
authors: YA
authors: Lee
authors: Seung-Jae
authors: SJ
authors: Hong
authors: Sang-Hoon
authors: SH
authors: Lee
authors: Hyung-In
authors: HI
authors: Yang
authors: Myung Chul
authors: MC
authors: Yoo
mesh_terms: D001172:Arthritis, Rheumatoid; D002478:Cells, Cultured; D004305:Dose-Response Relationship, Drug; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D005347:Fibroblasts / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D015870:Gene Expression / Q000187:drug effects; D006801:Humans; D053583:Interleukin-1beta / Q000494:pharmacology*; D020781:Matrix Metalloproteinase 1 / Q000096:biosynthesis / Q000235:genetics; D053509:Matrix Metalloproteinase 13 / Q000096:biosynthesis / Q000235:genetics; D061965:Matrix Metalloproteinase Inhibitors; D015398:Signal Transduction; D013583:Synovial Membrane / Q000166:cytology; D013654:Taurine / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D004791:Enzyme Inhibitors; D053583:Interleukin-1beta; D061965:Matrix Metalloproteinase Inhibitors; D013654:Taurine; C043410:N-chlorotaurine; D053509:Matrix Metalloproteinase 13; D020781:Matrix Metalloproteinase 1
references: Expert Opin Biol Ther. 2004 Jun;4(6):847-60
references: 15174967
references: Biochem J. 1997 Apr 1;323 ( Pt 1):13-6
references: 9173871
references: Immunol Today. 1997 Jul;18(7):320-4
references: 9238834
references: Immunopharmacology. 1998 Jul;40(1):27-38
references: 9776476
references: Proc Natl Acad Sci U S A. 1998 Nov 10;95(23):13859-64
references: 9811891
references: Mol Cell Biol. 1999 Jun;19(6):4431-42
references: 10330183
references: Clin Immunol. 2005 May;115(2):118-28
references: 15885632
references: Inflamm Res. 2005 Apr;54 Suppl 1:S21-2
references: 15928818
references: Front Biosci. 2006;11:529-43
references: 16146751
references: Joint Bone Spine. 2006 Jan;73(1):29-36
references: 16087381
references: Osteoarthritis Cartilage. 2006 Aug;14(8):749-58
references: 16549373
references: Int Immunopharmacol. 2006 Sep;6(9):1431-40
references: 16846837
references: Arthritis Rheum. 2006 Aug;54(8):2471-80
references: 16868967
references: Arthritis Rheum. 2006 Sep;54(9):2711-21
references: 16947381
references: Inflamm Res. 2006 Oct;55(10):446-55
references: 17109072
references: J Biol Chem. 2007 Apr 13;282(15):11110-21
references: 17311929
references: Arthritis Res. 2001;3(1):72-6
references: 11178129
references: J Immunol. 2000 Nov 15;165(10):5788-97
references: 11067938
references: J Immunol. 2001 Aug 1;167(3):1601-8
references: 11466382
references: J Immunol. 2001 Aug 15;167(4):2275-81
references: 11490015
references: Arthritis Res. 2002;4(2):117-25
references: 11879547
references: Shock. 2002 Apr;17(4):304-7
references: 11954831
references: Arthritis Res. 2002;4(3):157-64
references: 12010565
references: J Biol Chem. 2002 Jul 5;277(27):24049-56
references: 11983684
references: Arthritis Res. 2002;4 Suppl 3:S39-49
references: 12110122
references: J Biol Chem. 2002 Sep 20;277(38):35150-5
references: 12130632
references: Rheumatology (Oxford). 2002 Nov;41(11):1249-60
references: 12421997
references: Amino Acids. 2002;23(4):415-8
references: 12436209
references: Amino Acids. 2002;23(4):419-26
references: 12436210
references: Arthritis Rheum. 2003 Jun;48(6):1551-5
references: 12794822
references: Neurochem Res. 2004 Jan;29(1):117-26
references: 14992270
references: Rheumatology (Oxford). 2004 Jun;43 Suppl 3:iii2-iii9
references: 15150426
references: J Neuroimmunol. 2004 Aug;153(1-2):132-42
references: 15265671
references: Ann Rheum Dis. 1981 Aug;40(4):396-9
references: 7259331
references: Clin Chem. 1982 Aug;28(8):1758-61
references: 7094296
references: Arthritis Rheum. 1984 Aug;27(8):857-63
references: 6466394
references: J Biol Chem. 1985 Mar 25;260(6):3321-9
references: 3972827
references: J Clin Invest. 1986 Feb;77(2):645-8
references: 3003163
references: Am J Clin Nutr. 1986 Sep;44(3):398-404
references: 3092631
references: Methods Enzymol. 1986;132:569-85
references: 3821526
references: N Engl J Med. 1990 May 3;322(18):1277-89
references: 2271017
references: J Leukoc Biol. 1990 Aug;48(2):174-82
references: 2370482
references: Free Radic Biol Med. 1993 Dec;15(6):637-43
references: 8138190
references: FASEB J. 1994 Dec;8(15):1314-25
references: 8001745
references: J Immunol. 1995 May 1;154(9):4778-84
references: 7536781
references: J Leukoc Biol. 1995 Dec;58(6):667-74
references: 7499964
references: J Biol Chem. 1996 Jan 19;271(3):1544-50
references: 8576151
references: Annu Rev Immunol. 1996;14:397-440
references: 8717520
references: Am J Physiol. 1996 Jan;270(1 Pt 2):F123-30
references: 8769830
references: Immunopharmacology. 1996 Sep;34(2-3):89-95
references: 8886852
references: J Biol Chem. 1996 Nov 8;271(45):28509-15
references: 8910479
references: J Biol Chem. 1997 Mar 21;272(12):7608-16
references: 9065415
references: Genomics. 1997 Mar 1;40(2):222-33
references: 9119388